Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya.
Improvements in physical wellbeing during the first six months on antiretroviral therapy (ART) are well known, but little is known regarding long-term follow-up. We conducted a prospective cohort study among 222 HIV-positive adult tea plantation workers in western Kenya to assess wellbeing over their first two years on ART. Study subjects completed a standardized questionnaire during repeat ART clinic visits. A 30-day recall period was used to elicit the number of days when subjects experienced poor health and the number of days that pain made it difficult to complete usual activities at home and work. A seven-day recall period was used to assess the severity of bodily pain, nausea, fatigue, and rash. Prevalence of most symptoms declined over time. A median of seven days poor health during the first month on ART declined to three days in the 24th month (p=0.043). For pain making usual activities difficult, a median of seven days during the first month on ART fell to zero by 12 months (p< or =0.0001) but increased to three days by two years. Any bodily pain (range 59-83%) and fatigue (range 51-84%) over the past seven days were common through two years. However, pain and fatigue often over the past seven days declined over two years (from 24-10% (p=0.067) and 41-15% (p=0.002)). Skin rash was rare at all times, though higher at two years (8.6%) than any other time. Initial improvements in physical wellbeing were sustained over two years, however, increased pain and skin rash at year two may indicate problems as treatment programs mature. These improvements in physical wellbeing will be important in sustaining the long-term success of HIV treatment programs.
Fox
Matthew P
MP
Department of International Health, Center for Global Health and Development, School of Public Health, Boston University, Boston, MA, USA. mfox@bu.edu
McCoy
Kelly
K
Larson
Bruce A
BA
Rosen
Sydney
S
Bii
Margaret
M
Sigei
Carolyne
C
Shaffer
Douglas
D
Sawe
Fred
F
Wasunna
Monique
M
Simon
Jonathon L
JL
D000328:Adult; D000383:Agriculture; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D004526:Efficiency; D005076:Exanthema; D005221:Fatigue; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006304:Health Status; D006801:Humans; D007630:Kenya; D008297:Male; D008875:Middle Aged; D010146:Pain; D011788:Quality of Life; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D013662:Tea; D016896:Treatment Outcome; D055815:Young Adult
D019380:Anti-HIV Agents; D013662:Tea
AIDS Care. 2009 Nov;21(11):1343-56
20024710
AIDS. 2008 Jul;22 Suppl 1:S131-9
18664945
Qual Life Res. 2007 Aug;16(6):961-8
17468942
PLoS Med. 2007 Oct 16;4(10):e298
17941716
AIDS. 2008 Jan 30;22(3):421-5
18195569
Int J STD AIDS. 2002 Oct;13(10):683-90
12396538
HIV Med. 2007 Mar;8(2):92-5
17352765
J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):38-47
12514412
AIDS Care. 2004 Jul;16(5):649-61
15223534
AIDS. 2000 Jan 28;14(2):181-7
10708289
Psychosom Med. 2000 May-Jun;62(3):413-22
10845355
J Antimicrob Chemother. 2008 Mar;61(3):469-73
18174196
AIDS Care. 2005 Jul;17(5):579-88
16036244
Qual Life Res. 2007 Nov;16(9):1461-71
17899446
HIV Clin Trials. 2004 May-Jun;5(3):132-9
15248137
Epidemiol Infect. 2008 May;136(5):694-702
17599780
AIDS Care. 2007 May;19(5):626-36
17505923